Clinical Trials · NCT01930188
Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 1,231
- Start date
- Dec 2013
- Locations
- 141 sites, 18 countries
- Primary endpoint
- Change in HbA1c (Glycosylated Haemoglobin) From Baseline